EMA In The Clear Over Transparency In COVID-19 Product Assessments
Ombudsman Says Agency Showed ‘High Transparency Standards’
Executive Summary
The European Ombudsman has closed an inquiry into the European Medicines Agency’s practices with regard to coronavirus vaccines and treatments.
You may also be interested in...
Rasi To Ombudsman: No Risk Of Bias In EMA’s COVID-19 Drug Evaluations
European Medicines Agency chief Guido Rasi has responded to questions by the European Ombudsman about its COVID-19 Pandemic Task Force.
EMA Heeds Ombudsman’s Advice On Avoiding Perception Of Bias In Drug Evaluations
An inquiry by the EU Ombudsman has prompted the European Medicines Agency to introduce changes to ensure that its experts, who advise companies in the premarket phase, are not appointed to evaluate marketing applications for the same drugs.
Coronavirus Notebook: WHO Says Extra Vaccine Boosters Confer Some Limited Benefits, Emergex & Zosano Link Up On T Cell Vaccine Patch
International regulators have issued an updated statement on the benefits and safety of COVID-19 vaccines for use by health professionals, while the UK BioIndustry Association has welcomed a MAb licensing deal between AstraZeneca and UK-based biotech firm RQ Bio.